CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 09:57 ET
|
Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
US Healthcare Advertising Market Analysis Report 2024-2032: Increasing Presence of Generic and Me-too Drugs, Increased Consumer Reach through Mobile Advertising, Strict Rules and Regulations by FDA
March 08, 2024 06:35 ET
|
Research and Markets
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "US Healthcare Advertising Market Report by Product Type (Pharmaceuticals (Small Molecule Drugs), Biopharmaceuticals, Vaccines, Over-The-Counter (OTC)...
mRNA Vaccines in the Global Infectious Diseases Market: Opportunities, Challenges, Unmet Needs, Current Companies and Market Outlook
March 04, 2024 11:54 ET
|
Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines in Infectious Diseases Market Overview" report has been added to ResearchAndMarkets.com's offering.The report provides an assessment of...
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024 08:30 ET
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose...
Global BCG Vaccines Market Forecast Report: Compound Annual Growth Rate (CAGR) of 5.90% is Forecast Through the End of 2028
February 28, 2024 11:10 ET
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "BCG Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
February 28, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024 16:01 ET
|
Vaxcyte, Inc.
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...
Vaccine Collaboration and Licensing Deals Report: A Comprehensive Analysis of Biopharma Industry Agreements from 2016-2023
February 23, 2024 04:13 ET
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Biopharma sector witnesses a...
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
February 20, 2024 07:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...